Dr. Reddy's Laboratories Limited
Financials
Valuation Metrics
Dr. Reddy's Laboratories Limited's Market Cap is $11.80B. Ranked #813 of 3,118 in US market (top 26%), #559 of 1,644 on NYSE (top 34%), #38 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 14%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $11.80B | US#813/3,118 Sec#38/265 |
| Revenue | $3.77B | US#1,044/3,118 Sec#29/265 |
| Net Income | $376M | US#977/3,118 Sec#31/265 |
| Total Assets | $6.10B | US#1,295/3,118 Sec#36/265 |
| Net Assets | $4.06B | US#802/3,118 Sec#32/265 |
| Employees | 27,527 | US#422/3,118 Sec#16/265 |
| Value | ||
| P/E | 31.39x | US#1,619/3,118 Sec#42/265 |
| P/B | 2.90x | US#1,747/3,118 Sec#95/265 |
| P/S | 3.13x | US#1,784/3,118 Sec#55/265 |
| EV/EBITDA | 19.75x | US#1,894/3,118 Sec#49/265 |
| FCF Yield | 1.45% | US#2,107/3,118 Sec#71/265 |
| Profitability | ||
| ROE | 9.25% | US#1,442/3,118 Sec#48/265 |
| ROA | 6.16% | US#903/3,118 Sec#50/265 |
| Op. Margin | 10.57% | US#1,528/3,118 Sec#61/265 |
| Revenue Growth | -0.43% | US#2,230/3,118 Sec#134/265 |
| Earnings Growth | -41.61% | US#1,666/3,118 Sec#42/265 |
| Financial Health | ||
| Debt Ratio | 49.18% | US#552/3,118 Sec#138/265 |
| Total Debt | $763M | US#1,662/3,118 Sec#51/265 |
| FCF | $172M | US#1,457/3,118 Sec#53/265 |
| Cash | $119M | US#2,100/3,118 Sec#158/265 |
| Current Ratio | 1.90x | US#1,292/3,118 Sec#224/265 |
| Net Debt/EBITDA | 1.02x | US#977/3,118 Sec#44/265 |
| Dividend | ||
| Div. Yield | 0.64% | US#1,464/3,118 Sec#22/265 |
| Div. Growth | 5.17% | US#801/3,118 Sec#9/265 |
| Performance | ||
| 1Y Return | 6.32% | US#1,644/3,118 Sec#137/265 |
| 1M Return | 15.35% | US#595/3,118 Sec#39/265 |
| From 52W High | -9.83% | US#761/3,118 Sec#45/265 |
| 1Y MDD | -26.01% | US#1,008/3,118 Sec#48/265 |
| Trading | ||
| Volume | 1,673,724 shares | US#1,174/3,118 Sec#109/265 |
| Trading Value | $24M | US#1,842/3,118 Sec#137/265 |
Company Info
Dr. Reddy's Laboratories Limited, alongside its associated companies, functions as a holistic pharmaceutical entity with a global footprint. Its business operations are divided into several key divisions. The Global Generics segment is responsible for the manufacturing and sale of both prescription and over-the-counter finished pharmaceutical products. These offerings are available either under a proprietary brand or as generic formulations that are therapeutically identical to their branded equivalents. This segment also includes the company's biologics ventures. The Pharmaceutical Services and Active Ingredients (PSAI) division focuses on producing and distributing active pharmaceutical ingredients (APIs) and chemical intermediates, which serve as crucial building blocks for final drug products. Additionally, PSAI provides contract research services and produces custom-specified APIs and steroids for clients. The Proprietary Products segment is dedicated to the research and advancement of unique pharmaceutical formulations. The Others segment is actively involved in developing treatments, primarily for oncology (cancer) and inflammatory conditions. Dr. Reddy's addresses a broad spectrum of therapeutic areas, including gastrointestinal issues, cardiovascular health, diabetes, dermatological concerns, cancer, respiratory diseases, oral health, urological disorders, and nephrological conditions. The company has also established a partnership with Curis, Inc., centered on the discovery, development, and commercialization of small molecule antagonists designed for immuno-oncology and precision oncology targets. Founded in 1984, Dr. Reddy's Laboratories Limited maintains its principal office in Hyderabad, India.